Clinical utility of the nuclear-localized AR-V7 biomarker for treatment choice in metastatic castration-resistant prostate cancer.

Transl Androl Urol · 2020 · PMC7807368 · PMID 33457221

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

( 7 ) is highly significant in that it affords solid arguments to consider nuclear AR-V7 as a valuable tool coming in addition to clinical criteria to choose between ARSIs and taxanes in the complex situation of mCRPC.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.